This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...
You have to be a subscriber to view this page.

Perspective

Apr. 3, 2010

Description Restriction

The Federal Circuit's ruling on the written description requirement for patents wil have an immediate impact on inventors and the industry, writes Michael Rosen of Fish & Richardson.

By Michael M. Rosen

In a riveting tale of legislative sentence structure, history, and policy, the full Court of Appeals for the Federal Circuit held in Ariad v. Lilly, No. 2008-1248, that Ariad Pharmaceuticals' patent claims were invalid because they did not contain a sufficiently detailed description of its claimed invention - a method for reducing activity of a gene transcription factor.

While the ruling didn't come as muc...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up